Enliven Therapeutics Inc. (ELVN) Stock Forecast & Price Target
Enliven Therapeutics Inc. · NASDAQ
$53.74+1.00 (+1.91%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Enliven Therapeutics Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $62.00 to $80.00, so the covering firms are broadly aligned. The average target of $68.60 sits 28% above the current $53.74. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.41 next quarter toward $-2.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Strong Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Enliven Therapeutics Inc.
As of Jul, 5 of 5 firms rate ELVN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ELVN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.41
Range $-0.47 – $-0.37 · 3 analysts · +29% YoY
Next period, 3 analysts expect Enliven Therapeutics Inc. to earn $-0.41 a share (range $-0.47 – $-0.37), versus $-0.32 a year earlier. Full-year consensus is $-1.70, growing to $-2.33 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $7.1K next year.
Top analysts covering Enliven Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ELVN.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$80.00+48.9% to target
Overall win rate
55%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$64.00+19.1% to target
Overall win rate
38%
+ Follow
#3
Salveen Richter
Goldman Sachs
Buy
$67.00+24.7% to target
Coverage
—
+ Follow
#4
Salim Syed
Mizuho
Buy
$62.00+15.4% to target
Coverage
—
+ Follow
#5
DA
Dara Azar
Stifel Nicolaus
Buy
$80.00+48.9% to target
Coverage
—
+ Follow
ELVN stock forecast FAQ
What is ELVN's average 12-month price target?+
The 5 analysts with a live target average $68.60 for Enliven Therapeutics Inc. over the next 12 months, ranging from a $80.00 high to a $62.00 low.
Is ELVN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ELVN?+
The Street-high target is $80.00 (Stifel), and the Street-low is $62.00 (Mizuho). The average of all 5 active targets is $68.60.
How many Wall Street analysts cover ELVN?+
5 analysts have an active rating on Enliven Therapeutics Inc., and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ELVN?+
Among analysts who currently cover ELVN, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $80.00 target.
What is Enliven Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.41 per share (range $-0.47 – $-0.37) across 3 analysts. Full-year EPS is projected at $-1.70, rising to $-2.33 the following year.
How much revenue is Enliven Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $7.1K next year.
Have analysts been upgrading or downgrading ELVN lately?+
As of Jul, 5 of 5 firms rate ELVN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ELVN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
